Vertex Pharmaceuticals Inc., widely recognised for its cystic fibrosis treatments, is venturing into new therapeutic areas , signalling potential growth in new markets. The company is currently advancing its development of non-opioid analgesics, specifically candidate VX-548, which has demonstrated encouraging outcomes in clinical trials. This new drug represents...
Are you interrested in buying NASDAQ:VRTX ? I'm looking for a break confirmation of the 2-years trendline to evaluate a first entry in the 370s. Then the POC line could be a valid support to regain the trend.
In the wake of the opiod epidemic, brought on in part by the success of Oxycodone, a new exceptional drug is being developed by Vertex Pharmaceuticals (NASDAQ: VRTX). With the intention of providing relief from severe pain without the addictive properties of opioids, Vertex’s new drug could be on track to replicate the success of Oxycodone – making VRTX stock one...
As price action is currently receiving short term bearishness from sellers from being near all time highs, accumulation of shares are lessening however the uptrend has been strong overall. Look for more of a pullback leading into earnings and with strong support should provide another entry long into this uptrend that price has been on since DEC 2023. A good buy...
Our portfolio is up by more than 15% in the month of November. We are strictly following Mark Minervini's Trading Methodology. Here is a quick summary:
Mark Minervini's trading methodology, often encapsulated in his SEPA (Specific Entry Point Analysis) system, is a comprehensive approach to trading that emphasizes the importance of timing, risk management, and...
Vertex Pharmaceuticals Inc. shares were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
The stock jumped more than 10% Wednesday morning, on pace for its largest percentage gain in more than three years, and was set to cross the $100 billion market-capitalization threshold...
In the world of trading, there are a variety of strategies that investors can employ to maximize their returns. One such strategy that has gained popularity in recent years is the vertical spread bull put. This strategy involves buying a put option with a lower strike price and selling a put option with a higher strike price.
Understanding Vertical Spread Bull...
Hi traders,
let's have a look at VRTX analysis on daily timeframe.
The support at 342$ has been retested many times however, this time we are expecting support to fail.
If horizontal support fails and the price breaks upslopping support (blue line), it will look more bearish and short position can be taken.
We define 3 targets which are shown on the chart....
Vertex Pharmaceuticals (VRTX) has experienced a decline of around 5.84% in its share price over the past month. However, based on the provided facts, it appears that Vertex Pharmaceuticals is in a strong financial position and could be a good investment opportunity.
Here is the core logic behind this trading idea:
Net Income: Vertex Pharmaceuticals currently has...
We have added a new position and here is a link to the updated portfolio:
www.tradingview.com
VRTX had a positive earnings surprise on Nov 6th which pushed the price up to new highs. These new highs have been followed by a natural pullback which occured under low trading volume.
The new position has been added as the price broke through yesterdays high - a...
The 1-2-3-4-5 Impulse Wave (blue wave) formation on VRTX is nearly complete. We can see a rising wedge (white colour) after impulse wave 3. This is impulse wave 5, which can be in the form of a wedge. VRTX is consolidating at the top. It may make one last effort to reach the top, form a double top and then break down.
Another way to confirm formation of impulse...
Vertex Pharmaceuticals has been quietly sitting near record highs, and now some traders may look for movement to the upside.
The first pattern on today’s chart is the tight consolidation pattern since early August. VRTX barely fell despite a steeper pullback in the broader market -- a potential sign of relative strength.
The narrow range also pushed Bollinger...
The PEAD projected a bullish outlook for NASDAQ:VRTX after a positive under reaction following its earnings release placing the stock in drift A with an expected accuracy of 75%.
Price appears to have been in a Rectangle which is a consolidation pattern.
Rectangles are also known as Horizontal Trading Ranges and these can break up or down. This one broke to the upside.
Looks like a rising wedge formed which is bearish in the end, although price can break upward from a rising wedge. Price fell out of the wedge to the downside. Rising...
Entry: with price above 354.47
Volume: with volume greater than 2M
Target: 391 area
Stop: Depending on your risk tolerance; 342.3 gets you 3/1 Reward to Risk Ratio.
This swing trade idea is not trade advice and is strictly based on my ideas and technical analysis. No due diligence or fundamental analysis was performed while evaluating this trade idea. Do not take...
Vertex Pharmaceuticals broke out to new highs last month, and now it’s pulled back.
The first pattern on today’s chart is the price area around $325, near the peaks in December and January. VRTX has dipped to revisit that level. Is old resistance becoming new support?
Second, the drugmaker is attempting to hold the bottom of its Keltner Channel.
Third, some...
The PEAD projected a bullish outlook for NASDAQ:VRTX after a positive under reaction following its earnings release placing the stock in drift A with an expected accuracy of 66.67%.
